Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
7.17
-0.06 (-0.83%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Unicycive Therapeutics Employees
As of December 31, 2025, Unicycive Therapeutics had 22 total employees, including 21 full-time and 1 part-time employees. The number of employees decreased by 1 or -4.35% compared to the previous year.
Employees
22
Change (1Y)
-1
Growth (1Y)
-4.35%
Revenue / Employee
n/a
Profits / Employee
-$1,207,045
Market Cap
180.95M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| Protalix BioTherapeutics | 226 |
| Tonix Pharmaceuticals Holding | 142 |
| Cartesian Therapeutics | 75 |
| Precision BioSciences | 68 |
| Acumen Pharmaceuticals | 61 |
| Korro Bio | 58 |
| Corbus Pharmaceuticals Holdings | 36 |
UNCY News
- 19 days ago - Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf - Newsfile Corp
- 2 months ago - Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit - GlobeNewsWire
- 3 months ago - UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - GlobeNewsWire
- 3 months ago - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - GlobeNewsWire
- 4 months ago - Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) - GlobeNewsWire
- 5 months ago - Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf - Newsfile Corp